title: Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital.
abstract: OBJECTIVE
  Acute myeloid leukemia (AML) is the most common acute leukemia in adults. We documented the characteristics and results of treatment of patients with AML at a single reference center.
  
  
  METHODS
  Patients diagnosed with AML between June 2003 and July 2011 at a university hospital in northeast Mexico were studied. Overall survival (OS) and event-free survival (EFS) were determined, and risk factors were analyzed with respect to their influence on prognosis.
  
  
  RESULTS
  A total of 132 AML patients were included. Median age was 32 years. Complete remission (CR) was achieved by 55% of patients. CR was achieved by 65.1% of patients <60 years (n = 109), compared to 8.7% of those >60 years (n = 23; p < 0.001). In all, 39% of patients >60 years suffered an early death, compared to 14.7% of those <60 years (p < 0.001). OS for patients with AML was 35%, whereas EFS was 32%. On multivariate analysis, patients >60 years had a lower OS and EFS (p < 0.001). A total of 28% of patients received a transplant, and they had high er OS and EFS. Conclusions: Our patients were considerably younger and had remarkably lower survival rates than reported for other populations; those >60 years had a higher early death rate, and fewer of these patients achieved CR.
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Jaime-Pérez
authors.forename: Alma Sirenia
authors.initials: AS
authors.lastname: Brito-Ramirez
authors.forename: Monica Andrea
authors.initials: MA
authors.lastname: Pinzon-Uresti
authors.forename: Homero
authors.initials: H
authors.lastname: Gutiérrez-Aguirre
authors.forename: Olga G
authors.initials: OG
authors.lastname: Cantú-Rodríguez
authors.forename: José Luis
authors.initials: JL
authors.lastname: Herrera-Garza
authors.forename: David
authors.initials: D
authors.lastname: Gomez-Almaguer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016913:Blood Component Transfusion; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006785:Hospitals, University; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007278:Injections, Spinal; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology* / Q000628:therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000890:Anti-Infective Agents; D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D008942:Mitoxantrone; D008727:Methotrexate